By Jeff Kizzilah
Boehringer Ingelheim, one of the world’s leading pharmaceutical companies expansion is set to increase Boehringer Ingelheim’s global footprint in the region while strengthening the company’s commitment to improving human and animal health in Africa.
Boehringer Ingelheim, a leading research-driven biopharmaceutical company.
The new office will serve as the company’s headquarters for Sub-Saharan Africa region and is poised to expand the company’s global presence in the region.
Speaking during the event in Nairobi Mr. Mohammed Tawil Regional Managing Director and Head of Himan Pharma for IMETA region said,” Our thoughts is to expand the health care in this region by providing families with good healthier as well as those with loved ones across the impacted regions who are just starting a long journey.
He said that patients are at the core of the company’s focus and is committed to providing positive impact to people’s lives.
Boehringer Ingelheim leads by value through innovation, and caring for patients, and customers.
Marianne Abouelkheir General Manager and Head of Himan Pharma for LINEA,says the company explore emerging science and technology for but also beyond the Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.
Dr.Joseph Lenai the acting Director of the Intergovernmental and International health relations said Kenya will work with Boehringer Ingelheim to strengthen the Research & Development by focusing on core diseases for which we have built expertise over time and are actively investing from countries like Germany.